Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial[1] Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events* Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026 Dubai, 24 December … Continue reading Wegovy® pill approved in the US as first oral GLP-1for weight management